By reducing appetite and increasing feelings of fullness, GLP-1 medication enables individuals to better control their food intake and achieve sustainable weight management
As is typical for trials of agents to treat type 2 diabetes, the mean reduction in A1C with Januvia appears to be related to the degree of A1C elevation at baseline
467 An analysis of the tryptophan, tyrosine, purine pathways, and associated pathways revealed that in patients in remission, methionine levels were higher, while tryptophan and tyrosine levels were lower
Clinical evidence for this effect is limited, and responses vary between individuals
Historically, the main pill has been Rybelsus for type 2 diabetes (FDA Rybelsus label, 2025)
The medication also affects the vagus nerve and activates GLP-1 receptors throughout your gut, which can intensify sensations and alter how your body perceives hunger and satiety